GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

UK drugmaker’s new chief executive, Luke Miels, makes mark with deal for Boston-based biotech Nuvalent Business live – latest updates GSK’s new boss, Luke Miel…

In breve

<article class="opinion default clearfix">

<h2> <a href="https://www.middleeasteye.net/opinion/israels-military-adventures-have-backfired-and-public-losing-patience" rel="bookmark"> <span class="field field-title">Israel's military adventures have backfired - and

Contesto

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm UK drugmaker’s new chief executive, Luke Miels, makes mark with deal for Boston-based biotech Nuvalent Business live – latest updates GSK’s new boss, Luke Miels , has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications. The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash. Continue reading... According to the collected source material from www.theguardian.com, UK drugmaker’s new chief executive, Luke Miels, makes mark with deal for Boston-based biotech Nuvalent Business live – latest updates GSK’s new boss, Luke Miels , has struck one of the British…

Lettura DEO

Verdetto: publish
Confidenza: 82/100

Deterministic fallback judge output. Libre judge fallback via DeepSeek Gamma.

Categoria: cronaca